Compounds > 2-(5-bromo-2-pyridylazo)-5-(n-n-propyl-n-3-sulfopropylamino)phenol
Page last updated: 2024-11-07

2-(5-bromo-2-pyridylazo)-5-(n-n-propyl-n-3-sulfopropylamino)phenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(5-bromo-2-pyridylazo)-5-(N-n-propyl-N-3-sulfopropylamino)phenol: used for determination of zinc in blood; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133727
SCHEMBL ID1057997
MeSH IDM0105862

Synonyms (12)

Synonym
5-br-paps
2-(5-bromo-2-pyridylazo)-5-(n-n-propyl-n-3-sulfopropylamino)phenol
1-propanesulfonic acid, 3-((4-((5-bromo-2-pyridinyl)azo)-3-hydroxyphenyl)propylamino)-
81608-06-2
SCHEMBL1057997
91599-24-5
2-(5-bromo-2-pyridylazo)-5-[n-n-propyl-n-(3-sulfopropyl)amino]phenol
2-(5-bromo-2-pyridylazo)-5-(n-propyl-n-sulfopropylamino)phenol
3-[{(4e)-4-[(5-bromo-2-pyridinyl)hydrazono]-3-oxo-1,5-cyclohexadien-1-yl}(propyl)amino]-1-propanesulfonic acid
3-[4-[(5-bromopyridin-2-yl)diazenyl]-3-hydroxy-n-propylanilino]propane-1-sulfonic acid
2-(5-bromo-2-pyridylazo)-5-[n-n-propyl-n-(3-sulfopropyl)amino]phenol disodium dihydrate (5-br-paps)
3-((4-((5-bromopyridin-2-yl)diazenyl)-3-hydroxyphenyl)(propyl)amino)propane-1-sulfonic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's2 (22.22)18.2507
2000's1 (11.11)29.6817
2010's1 (11.11)24.3611
2020's3 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.77 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
diphosphoric acid
diphosphoric acid : An acyclic phosphorus acid anhydride obtained by condensation of two molecules of phosphoric acid.		3.1410acyclic phosphorus acid anhydride;
phosphorus oxoacid		Escherichia coli metabolite
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		2.1710acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
sodium citrate, anhydrous
Sodium Citrate: Sodium salts of citric acid that are used as buffers and food preservatives. They are used medically as anticoagulants in stored blood, and for urine alkalization in the prevention of KIDNEY STONES.. sodium citrate : The trisodium salt of citric acid.		2.1710organic sodium saltanticoagulant;
flavouring agent
salicylaldoxime
[no description available]		2.1710
homocysteine
Homocysteine: A thiol-containing amino acid formed by a demethylation of METHIONINE.. homocysteine : A sulfur-containing amino acid consisting of a glycine core with a 2-mercaptoethyl side-chain.. L-homocysteine : A homocysteine that has L configuration.		2.3110amino acid zwitterion;
homocysteine;
serine family amino acid		fundamental metabolite;
mouse metabolite
pyrophosphate
Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.		3.1410diphosphate ion
ConditionIndicatedRelationship StrengthStudiesTrials
2019 Novel Coronavirus Disease
[description not available]		02.610
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		03.1410
Basedow Disease
[description not available]		03.3811
Graves Disease
A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).		03.3811
Thyrotoxicosis
A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.		03.3811